Concepedia

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia

Yingchi Zhang, Yufeng Gao, Hui Zhang, Jingliao Zhang, Fuhong He, Aleš Hnı́zda, Maoxiang Qian, Xiaoming Liu, Yoshihiro Gocho, Ching‐Hon Pui,

Blood · 2018 · 76 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

Key Points AGGF1-PDGFRB is a novel oncogenic fusion gene in Ph-like ALL. Genomic profiling and functional studies identified a novel PDGFRB mutation directly related to TKI resistance.

References

13

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

Kathryn G. Roberts, Yongjin Li, Debbie Payne-Turner et al. · New England Journal of Medicine · 2014 · 1.4K citations · Full text

, , +17

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

Kathryn G. Roberts, Ryan D. Morin, Jinghui Zhang et al. · Cancer Cell · 2012 · 718 citations · Full text

, , +16

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Kirk R. Schultz, W. Paul Bowman, Alexander Aledo et al. · Journal of Clinical Oncology · 2009 · 709 citations · Full text

, , +16

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031

Kirk R. Schultz, Andrew J. Carroll, Nyla A. Heerema et al. · Leukemia · 2014 · 449 citations

, , +11

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget et al. · Blood · 2016 · 326 citations · Full text

, , +9